Close
Xylem
Novotech

Press Releases

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

Eli Lilly and Company and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary...

FedEx Distribution of COVID-19 Vaccines Grows, Reaches 100 Million Vaccine Doses Delivered

For more than a year, FedEx has been on the frontlines of the COVID-19 pandemic, delivering pharmaceuticals, personal protective equipment, critical medical supplies and e-commerce shipments to communities around the world impacted by this pandemic. Today, we mark an important...

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the Company's effort to begin...

Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced...

Moderna Announces Shipment of 100 Millionth Dose of its COVID-19 Vaccine to the U.S. Government

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine to the U.S. Government. More than 67 million doses of the Moderna COVID-19 Vaccine...

Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Advanced Therapy...

Lilly, Vir And GSK Report Positive Topline Data From COVID-19 Trial Of Bamlanivimab With Vir-7831

Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป